Methotrexat Stada

Methotrexate, the active ingredient in Methotrexat Stada, is an antimetabolite (folate antagonist) presented as an injectable solution for intramuscular or subcutaneous use. It is employed to treat autoimmune disorders, certain cancers, and specific gestational conditions in adult patients.

GNH USA supplies Methotrexat Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Methotrexate is used across several disease families, primarily autoimmune disorders, malignancies, and gestational trophoblastic conditions.

- Rheumatoid arthritis: reduces joint inflammation and disease progression. - Psoriasis: slows skin cell proliferation and improves plaque appearance. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: inhibits tumor growth and induces apoptosis. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention. - Gestational trophoblastic disease: promotes resolution of abnormal placental growth.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common after injection. - Fatigue: persistent tiredness reported by many patients. - Oral mucositis: painful sores or ulceration in the mouth. - Elevated liver enzymes: mild transaminitis detectable on labs. - Cytopenias: reduced white blood cells or platelets. - Alopecia: temporary hair thinning or loss.

Serious or Rare Side Effects: - Severe liver toxicity: potential for fibrosis or cirrhosis. - Pulmonary fibrosis: interstitial lung disease with dyspnea. - Life‑threatening infection: due to bone‑marrow suppression. - Bone‑marrow aplasia: profound pancytopenia. - Renal failure: acute kidney injury from precipitation. - Anaphylactic reaction: rare but possible hypersensitivity.

When prescribing methotrexate, clinicians should observe several safety measures to minimize risk.

- Pregnancy: contraindicated (Category X); avoid use in pregnant or planning patients. - Renal function: assess baseline creatinine; adjust or avoid if severe impairment. - Hepatic function: monitor transaminases regularly; avoid in active liver disease. - Hematologic monitoring: perform complete blood counts before and during therapy. - Infection risk: screen for latent infections and defer use in active infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - NSAIDs: increase methotrexate toxicity by reducing renal clearance. - Penicillins (e.g., ampicillin): may potentiate bone‑marrow suppression. - Sulfonamides: can enhance hematologic adverse effects. - Live vaccines: risk of severe infection due to immunosuppression. - Proton pump inhibitors: may alter absorption and increase exposure.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppression; monitor blood counts. - Warfarin: methotrexate may enhance anticoagulant effect; check INR. - Oral contraceptives: reduced efficacy; advise alternative contraception. - Allopurinol: may increase methotrexate levels; adjust dose if needed. - Trimethoprim‑sulfamethoxazole: heightened risk of myelosuppression.